NASDAQ: BRNS - Barinthus Biotherapeutics plc

Rentabilidade por seis meses: -63.53%

Cronograma de promoção Barinthus Biotherapeutics plc


Sobre a empresa

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

Mais detalhes
The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Цена ао 2.4
Выручка 0.0069
P/E 17.08
P/S 1541.67
P/BV 1.64
ISIN US91864C1071
Сайт https://www.barinthusbio.com
EBITDA -0.0254
EV/EBITDA 0.3797
Число акций ао 0.03839 млрд
Валюта usd
IPO date 2021-04-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Alteração de preço por dia: -3.23% (1.24)
Alteração de preço por semana: +1.69% (1.1801)
Alteração de preço por mês: -2.44% (1.23)
Alteração de preço em 3 meses: -16.03% (1.429)
Mudança de preço em seis meses: -63.53% (3.29)
Mudança de preço por ano: -64.6% (3.39)
Mudança de preço em 3 anos: -92.45% (15.9)
Mudança de preço desde o início do ano: -59.6% (2.97)

Subestimação

Nome Significado Nota
P/S 167.83 1
P/BV 0.7226 10
P/E 0 0
EV/EBITDA -0.0845 0
Total: 5.13

Eficiência

Nome Significado Nota
ROA, % -34.33 0
ROE, % -39.42 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.1826 10
Total: 9.4

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -88.33 0
Rentabilidade Ebitda, % 179.78 10
Rentabilidade EPS, % 213.89 10
Total: 8

Instituições Volume Compartilhar, %
M&G INVESTMENT MANAGEMENT LTD 5197349 13.48
Alphabet Inc. 1513644 3.92
HSG Holding Ltd. 1420473 3.68
DC Funds, LP 642204 1.67
BlueCrest Capital Management Ltd 542673 1.41
Baird Financial Group, Inc. 196296 0.51
Johns Hopkins University 107968 0.28
Ipswich Investment Management Company, INc. 23075 0.06
Renaissance Technologies, LLC 21400 0.06
Morgan Stanley 21215 0.06

Supervisor Cargo Pagamento Ano de nascimento
Mr. William J. Enright MBA CEO & Director 969.44k 1962 (62 ano)
Ms. Sarah Gilbert Co-Founder 48.98k
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor 61.61k
Ms. Gemma Brown CFO & Company Secretary N/A 1991 (33 ano)
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 593.48k 1979 (45 anos)
Mr. Graham Griffiths Chief Operating Officer 522.23k 1979 (45 anos)
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations N/A
Bernie McDonald Head of IP N/A
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies N/A
Dr. Leon Hooftman M.D. Chief Medical Officer

Endereço: United Kingdom, Harwell OX DF, Zeus Building - abrir no Google Maps, abrir mapas Yandex
Site: https://www.barinthusbio.com